Replies to post #111479 on Biotech Values

[poorgradstudent]

JAK / RA:

I just figured taking the more robust sets would be advantageous.

Agreed that the INCY data aren't showing anything meaningfully different than PFE. One has to presume PFE's first mover advantage will be a meaningful hurdle for JNJ.